Kisspeptin is the upstream signal the brain whispers to wake the reproductive hormone axis.

The short version

Kisspeptin is a small protein the brain makes to switch on the body's reproductive system. It is not a sex hormone itself. It is the first signal in the chain: a tiny group of hypothalamic neurons fire kisspeptin, that wakes GnRH (the hormone the brain uses to call the pituitary gland), and GnRH then tells the pituitary to release LH and FSH — the two hormones that drive ovulation in women and testosterone in men. In studies, kisspeptin has reliably pushed up LH within minutes. Researchers have tested it as a gentler trigger for IVF, as a way to restart cycles in women who have lost their periods, and as a probe of sexual-desire brain circuits. Two cautions lead every page here: kisspeptin is investigational — no health agency anywhere has approved it for any use — and its effect fades if it is given continuously or at high doses, because the receptor tires within days (a quirk called tachyphylaxis). What people report — including the downsides — is on the effects page.

What is kisspeptin

Kisspeptin is the product of the KISS1 gene (chromosome 1q32), and it is the principal upstream activator of GnRH neurons — the master switch sitting one step above the reproductive axis ^[1]. It binds KISS1R, a receptor first catalogued as the orphan GPR54, on the surface of hypothalamic neurons ^[1]. The proof that this signal is essential came from human genetics: people who inherit loss-of-function mutations in GPR54 fail to enter puberty, and mice lacking the receptor reproduce that phenotype exactly ^[1].

Kisspeptin acts upstream of GnRH. It does not supply LH, FSH, or testosterone — it tells the body's own neurons to release them. That distinction matters: kisspeptin is not a GnRH analog and not a sex steroid. It is the conductor's first downbeat, not the music. The signal is fired by KNDy neurons (clusters in the arcuate nucleus that co-express kisspeptin, neurokinin B and dynorphin — together the proposed pulse generator that paces the whole axis) ^[2].

Kisspeptin peptide — the two isoforms that carry the signal

The KISS1 precursor is cut into a family of fragments that all end in the same Arg-Phe-amide tail the receptor reads. Two dominate the research: a short bright flare and a longer burn.

The kisspeptin peptide known as kisspeptin-10 is the ten-residue C-terminal fragment — Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH2, about 1302.5 Da, with a plasma half-life near 4 minutes. It is the fast, sharply-rising signal ^[3]. The fifty-four-residue kisspeptin-54 (originally named metastin, about 5857 Da) resists the plasma enzymes longer and sustains its action — its measured human half-life is 27.6 ± 1.1 minutes ^[8]. At matched infusion rates the two produce comparable acute gonadotropin responses in men; the difference is duration, not direction ^[9]. Reading kisspeptin by isoform is the lens of this digest, and it runs through every page.

Why this is not a supplement

Search results pair kisspeptin with the word supplement, so it is worth saying plainly: kisspeptin is not a dietary supplement. It is an investigational compound. Every human finding summarized here comes from Phase 1 or Phase 2 research run with pharmaceutical-grade peptide under medical supervision — much of it from Imperial College London and collaborators ^[7]. A 2025 systematic review counted 29 interventional clinical trials across applications from secondary amenorrhea to IVF triggering and noted comparatively few side effects, while confirming that no kisspeptin product is approved by any regulator for any indication ^[7].

That honesty cuts both ways. The trial signal is genuine and reproducible; the consumer record is thin, because kisspeptin is not a sold product and there is little for an ordinary person to report. We keep the Kisspeptin research and the labeled-anecdote Kisspeptin effects in separate rooms for exactly that reason.